Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus XOFIGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus XOFIGO.
INDIUM IN 111 CHLORIDE vs XOFIGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
Radium-223 dichloride is a calcium-mimetic alpha particle-emitting radiopharmaceutical that forms complexes with bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The alpha particles induce double-strand DNA breaks in adjacent cells, resulting in cytotoxic effects.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
55 kBq (1.49 microcurie) per kg body weight, intravenous injection every 4 weeks.
None Documented
None Documented
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
The terminal elimination half-life of radium-223 dichloride is approximately 11 days (range 7–14 days), reflecting the slow turnover of radium in bone.
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Radium-223 dichloride is primarily excreted via the feces. Approximately 75% of the administered dose is eliminated in feces within 7 days, with a smaller fraction (about 5%) excreted in urine.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical